Mana Pharma produces an OTC drug and earns its entire revenue from it. This OTC drug reduces lethargy and tiredness and has been a steady revenue earner for Mana Pharma. The product is not under any patent protection but has a strong brand and is able to generate stable growth and profit margins and this is expected to continue for the foreseeable future. Mana Pharma is 100% equity financed and is expected to earn $ 120 per share as profit in the coming year. Currently the firm earns a return on investment of 20% and has a retention ratio of 50% of earnings. The cost of equity of Mana Pharma is 15%. Mana Pharma is faced with a new investment opportunity which requires a one-time investment of $ 30 per share in year 1. This new project will generate a return of 5% on invested capital each year forever. The opportunity cost of this project is also 15%. Mana Pharmas management will continue to invest in the older product as scheduled and the investment in the new project will be funded through a cut in dividend of $30. What is the value of Mana Pharmas stock price today with this new project?

ANSWER IS EITHER 1182.6 or 1158.7 ( explain which and why)